Effectiveness of a modified doxorubicin-etoposide-methylprednisolone regimen for the treatment of refractory or relapsed macrophage activation syndrome in adults

Pol Arch Intern Med. 2022 Mar 30;132(3):16226. doi: 10.20452/pamw.16226. Epub 2022 Mar 7.

Authors

Lingbo He¹, Zhili Jin¹, Menghan Liu¹, Ruoxi Zhang¹, Zhao Wang¹, Yini Wang²

Affiliations

¹ Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
² Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Department of General Practice, Beijing Friendship Hospital, Capital Medical University, Beijing, China. wangyini@ccmu.edu.cn

PMID: 35253415
DOI: 10.20452/pamw.16226

No abstract available

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols
Doxorubicin / therapeutic use
Etoposide
Humans
Macrophage Activation Syndrome* / drug therapy
Methylprednisolone / therapeutic use
Salvage Therapy

Substances

Etoposide
Doxorubicin
Methylprednisolone